Fritextsökning
Artiklar per år
Innehållstyper
-
High-tech companies are increasingly focusing on health
Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more about them advancing their positions,” says Anna Lefevre Skjöldebrand, CEO of Swedish Medtech.
-
Annexin tar in kapital för fortsatt satsning inom ögonsjukdom
Stockholmsbaserade Annexin Pharmaceuticals tar in upp till 35,6 miljoner kronor genom en företrädesemission.
-
“You discover one thing – and then 10 new questions arise”
COVID-19, diabetes, heart disease, and the impact of dog ownership on humans are just some of multitasker Tove Fall’s areas of research. However, her current focus is on her next field: the role of gut flora in human health.
-
The physician at the tech giant: “Observations in the emergency room made my mind up”
When Nasim Farrokhnia was in third grade at school in Tehran, the capital of Iran, her father gave her a book about Marie Curie, which soon became her favourite book. Perhaps her interest in science was born there and then, as science and new technology have since been a constant feature of her working life. Today, she is a Healthcare Manager in Microsoft’s Western Europe team.
-
Alzecure ser dubbel verkan med läkemedelsplattform
Forskningsbolaget Alzecure Pharma, som arbetar med projekt inom Alzheimers sjukdom, ser med Alzstatinplattformen möjlighet att motverka Alzheimers sjukdom på två olika sätt. Dels genom minskad produktion av ett skadligt protein, dels genom att förändra förhållandet mellan vissa specifika amyloidbeta (Aß) peptider i hjärnan.
-
The first drugs to slow down Alzheimer’s – but what does it mean for patients?
New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the right patients be found in time, and will the healthcare system’s resources be sufficient? Life Science Sweden has spoken to Swedish researchers in Alzheimer’s who voice cautious hope but also see further challenges.
-
700 personer varslas i Region Sörmland
Region Sörmland ska minska sina kostnader med en halv miljard kronor under nästa år och har anmält ett varsel för 700 medarbetare. Regionens läkemedelscentrum är en av de verksamheter där antalet anställda kan minska.
-
Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”
With mixed emotions, Charlotta Gummeson will leave her position as CEO of Sahlgrenska Science Park in October. “It feels sad and exciting at the same time. I’ve been in the thick of things and part of the development for so long now, but I’m also looking forward and thinking about all the new things that there will be in a freer role,” she says to Life Science Sweden
-
Pfizer’s Paxlovid is being tested against post-COVID in a major Swedish study
In a new study conducted at the Karolinska University Hospital, Pfizer’s COVID drug, Paxlovid, is now being tested in patients with post-COVID. The study is one of the most extensive studies in the world currently being conducted for a drug for post-COVID.
-
19 medicines in Sweden are under investigation in a major EMA inquiry
19 medicines marketed in Sweden are affected by an ongoing extensive European investigation into suspected fraud at an Indian contract research organisation. Among them are medicines for HIV, epilepsy, cancer and Parkinson’s, which may be withdrawn
-
Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients
In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.
-
Petter Brodin får pris för forskning inom pediatriken
KI-professorn och barnläkaren, Petter Brodin tilldelas Oscar Medins pris 2023 av Svenska Läkaresällskapet.
-
Heidi Stensmyren is eager for new challenges in the biotech industry
Heidi Stensmyren has served as President of the Swedish Medical Association, held a managerial position at Karolinska University Hospital and is now Medical Director at a biotech company. “I’m curious and like to have influence, so I’ve often chosen management roles,” she says.
-
Vaccinationsbolag i konkurs
Vaccinationsföretaget Legehuset Sverige har försatts i konkurs.
-
CROs in drug development: "We use our expertise to speed up the process
Consultancy firms have become an increasingly important part of drug development. “It’s a trend and a business model that works, and we see no indication that it will change,” says Helena Lüning of the industry organisation ASCRO.
-
Muterad fågelinfluensa i Finland
Fem farmer för pälsdjur i Finland har en muterad variant av fågelinfluensavirus.
-
Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president
In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According to the reporter Theo Baker, who first reported the story, Tessier-Lavigne “rewarded the winners and punished the losers”. Here is the background of the story which has shaken the American scientific community over the summer.
-
Tar roll på Quay Pharmaceuticals
Jörn Mars går in som Business Development Director Scandinavia på företaget SGS Quay Pharmaceuticals.
-
Uppgörelse klar om Henrietta Lacks odödliga celler
Sedan över 70 år lever Henrietta Lacks celler vidare i laboratorier världen över, och har bidragit till medicinsk forskning som räddat otaliga liv. Själv visste hon inte ens om att cellproverna togs och ingen kompensation har getts – förrän nu.
-
The Swedish Life Science Office: “We lost in both coordination and manpower”
Since the turn of the year, the Swedish government’s life science office has operated at a lower capacity. Life Science Sweden has spoken to Pontus Holm, Departmental Secretary at the office, about the ongoing work.
-
Neanderthal gene variants may cause Viking disease
A new study suggests that the so-called Viking disease, which affects the hand function in many older people, may be linked to gene variants inherited from Neanderthals.
-
Lucy Robertshaw: Artificial intelligence – is this really going to transform a patient’s life?
In a column Lucy Robertshaw reflects on how AI and new regulations will affect healthcare, innovation and the lives of future patients.
-
Getinge stärker närvaron på läkemedelsområdet i miljardaffär
Getinge förvärvar amerikanska High Purity New England, som tillverkar engångsprodukter för bioprocesser. Den svenska medtech-jätten betalar närmare 1,3 miljarder direkt, men affären kan växa till att kliva över tremiljarderstrecket.
-
This is the future location of the new national innovation cluster
Mölndal and Goco Health Innovation City will be the site of a new national innovation cluster for advanced therapies. The business community and the Swedish government are splitting the costs of the project, which is expected to produce new treatments for common diseases such as cancer and diabetes.
BREAKING